证券代码：688016 证券简称：心脉医疗 公告编号：2026-004 上海微创心脉医疗科技（集团）股份有限公司 2025年年度业绩快报公告 报告期内，公司实现营业总收入135,063.27万元，同比增长11.96%；实现营业利润65,389.17万元，同比 下降1.10%；实现利润总额65,337.47万元，同比增长0.18%；归属于母公司所有者的净利润56,321.31万 元，同比增长12.17%；归属于母公司所有者的扣除非经常性损益的净利润50,216.70万元，同比增长 26.97%；基本每股收益4.65元，同比增长14.25%。报告期末，公司总资产464,046.77万元，较年初增长 8.13%；归属于母公司的所有者权益407,565.93万元，较年初增长7.48%；归属于母公司所有者的每股净 资产33.63元，较年初增长9.03%。 2、影响经营业绩的主要因素 报告期内，公司创新产品在巩固国产领先优势的基础上，通过下沉市场、提供定制化治疗方案以及产品 升级迭代，加速推广新品、替换老产品等策略，推动市占率稳步提升，但考虑到2024年市场价格治理因 素影响的延续性，公司部分产品价格及推广策略的调整因素 ...

Core Viewpoint - MicroPort Medical (00853) reported a revenue of approximately 1.351 billion yuan for HeartPulse Medical (688016.SH) in 2025, marking a year-on-year increase of 11.96%, with a net profit attributable to the parent company of about 563 million yuan, up 12.17% year-on-year, and basic earnings per share of 4.65 yuan [1] Group 1: Financial Performance - The total revenue for the reporting period was approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - The net profit attributable to the parent company was around 563 million yuan, showing a year-on-year increase of 12.17% [1] - Basic earnings per share were reported at 4.65 yuan [1] Group 2: Product Development and Market Strategy - The company has accelerated the promotion of new products and replacement of old products through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - The company launched multiple innovative products in the domestic market, including the Cratos branched aortic stent graft system and other medical devices, with a total of 23 products receiving NMPA registration and 11 products obtaining registration in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products like the Aegis II abdominal aortic stent graft system and Hector thoracic multi-branch stent graft system progressing through various stages of clinical trials and regulatory submissions [3] Group 3: International Sales and Market Expansion - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of the company's total revenue [1] - The company is actively pursuing collaborations with leading regional clients globally and advancing the market access and promotion of aortic and peripheral interventional products in Europe, Latin America, and Asia-Pacific [1] - The company’s products are now sold in 49 countries and regions, including China [1]

公司新增多款创新产品在国内获批上市，包括 Cratos 分支型主动脉覆膜支架系统、经颈静脉肝内穿刺 套件、聚乙烯醇栓塞微球。公司累计 23 款产品获得 NMPA 首次注册证，11 款产品在 28 个海外市场获 得首次注册证;累计获得海外产品注册证 110 余张，其中 6 款产品获得 CE 认证，3 款产品获得欧盟定制 证书。 除上述产品外，公司在研产品稳步推进，管线丰富，其中 Aegis II 腹主动脉覆膜支架系统完成注册资料 递交;Hector 胸主多分支覆膜支架系统已进入国内上市前多中心临床阶段，且于报告期内进入国家创 新"绿色通道"，并已通过欧盟定制方式实现商业化，同时该产品美国 Breakthrough Device Designation 申请已提交 FDA;胸腹主动脉覆膜支架系统(定制)已获得国内备案证;髂动脉分支覆膜支架系统即将进入 临床试验启动阶段。外周业务方面，外周介入微导管、可解脱带纤维毛栓塞弹簧圈、机械血栓切除导 管、新一代外周裸球囊导管预计 2026 年获批上市;膝下药物球囊扩张导管、TIPS 覆膜支架系统已完成 注册递交;外周血管药物洗脱支架系统处于临床植入阶段。同时，公司创新产品的 ...

Investment Rating - The report maintains a "Buy" rating for the company, with projected PE ratios of 42, 34, and 27 for the years 2025, 2026, and 2027 respectively [4] Core Insights - The company is expected to achieve a revenue of 2.584 billion RMB in 2025, representing a year-on-year growth of 25%. The net profit attributable to the parent company is projected to be 821 million RMB, up 22% year-on-year [2] - The company's core product, PFA, has been well-promoted, leading to synergistic growth. The company emphasizes cost control, focusing R&D and sales expenses on market promotion, clinical validation, and next-generation product development [2] - The product pipeline is continuously advancing, with new products in coronary and peripheral business expected to enter a harvest phase. The company is actively conducting various marketing activities to enhance product coverage and admission rates [3] Financial Projections - The projected net profits for the company from 2025 to 2027 are 821 million RMB, 1.009 billion RMB, and 1.290 billion RMB, reflecting growth rates of 22%, 23%, and 28% respectively [4] - Revenue growth rates are expected to be 25.08% in 2025, 22.52% in 2026, and 26.85% in 2027 [9] - The diluted earnings per share are forecasted to be 5.818 RMB in 2025, 7.157 RMB in 2026, and 9.147 RMB in 2027 [9]

Core Viewpoint - The company, Xinmai Medical, has seen a stock price increase of 3.1% this week, closing at 97.98 yuan, with a total market capitalization of 12.077 billion yuan, ranking 27th in the medical device sector and 1716th in the A-share market [1] Company Announcements - Xinmai Medical's wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate for polyvinyl alcohol embolization microspheres, intended for the treatment of hypervascular solid organ malignant tumors [1] - This product marks the company's first embolization product in the field of tumor interventional therapy, with the registration certificate valid from January 28, 2026, to January 27, 2031 [1] - The company has multiple other tumor interventional products that have been approved or are under research, but actual sales will depend on market promotion efforts, making future revenue impact unpredictable [1]

Group 1 - Sileck's subsidiary received a project designation letter from a South Korean battery customer, expected to supply approximately 360 million cylindrical battery shells from 2027 to 2031 [1] - Fuguang Co.'s major shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 481.68 million shares [2] - Beixin Road and Bridge's consortium won a contract for a project worth 1.145 billion yuan, with two segments valued at 223.1 million yuan and 921.5 million yuan respectively [3] Group 2 - Jianyou Co.'s subsidiary received FDA approval for sodium selenite injection, aimed at providing selenium for parenteral nutrition in adults and pediatric patients [4] - China Galaxy received approval to publicly issue subordinated bonds totaling up to 20 billion yuan [6] - Changjiang Electric Power announced a cash dividend of 0.21 yuan per share, totaling 5.138 billion yuan [7] Group 3 - Zhongjin Company received approval to publicly issue corporate bonds totaling up to 20 billion yuan [8] - Daon Co. received a decision from the State Administration for Market Regulation not to conduct further antitrust review on its acquisition of Ningbo Aisikai Synthetic Rubber Co. [10] - Palm Co. won a project worth approximately 228 million yuan, which is expected to account for 7.44% of its audited revenue for 2024 [11] Group 4 - Kang En Bei's subsidiary received approval for clinical trials of TFA003 tablets for diabetic nephropathy [13] - Xinmai Medical's subsidiary obtained a medical device registration certificate for polyvinyl alcohol embolization microspheres [14] - Guangsheng Tang's innovative hepatitis B drug completed the enrollment of 578 participants in its Phase III clinical trial [15] Group 5 - Pianzaihuang's controlling shareholder received a loan commitment for up to 450 million yuan to support share buybacks [16] - Liya De plans to invest up to 100 million yuan in an industry fund focused on commercial aerospace [17] - Zhongwen Online plans to collaborate with Tencent on animation micro-short drama licensing, with an expected cooperation amount of 23.2 million yuan [19] Group 6 - Yungsheng Technology is planning to acquire control of Fengrui Fluorine Industry, with its stock continuing to be suspended [22] - Yinbang Co. received a sales order from HOLTEC ASIA for approximately 280 million yuan, expected to positively impact its operations in 2026 and 2027 [23] - Pailin Bio's subsidiary received a drug registration acceptance notice for human coagulation factor IX [24] Group 7 - Dao Dao Quan plans to apply for soybean oil delivery warehouse qualifications from the Dalian Commodity Exchange [25] - Qizheng Tibetan Medicine's subsidiary received a registration certificate for a traditional Chinese medicine product in Macau [26] - Vili Medical received EU MDR certification for multiple products [27][28] Group 8 - CITIC Bank plans to increase its investment in its wholly-owned subsidiary by 2 billion yuan [29] - Hayao Co. received approval for the consistency evaluation of its injectable drugs [30] - Zhifei Biological's freeze-dried varicella vaccine clinical trial received approval [31] Group 9 - Huibo Pu signed a contract worth 225 million USD for the Naft Khana oilfield recovery project [32] - Zhonggu Logistics plans to invest in the construction of two 6000 TEU container ships, with a total contract amount not exceeding 1.16 billion yuan [33] - Chongqing Beer reported a 10.43% increase in net profit for 2025, with revenue of 14.722 billion yuan [34] Group 10 - Huanxu Electronics reported a 12.16% increase in net profit for 2025, with revenue of 59.195 billion yuan [35] - Chengzhi Co.'s subsidiary successfully completed trial production of a high molecular weight polyethylene project [36] - Guangyang Co. signed a strategic cooperation agreement with Shenzhen Xuanchuang and Huangshan Guangyang [37]

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd. (referred to as "Tuomai Medical"), has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The product represents a significant advancement in the company's medical device offerings [1]

Group 1 - The core point of the article is that Shanghai MicroPort MedBot (Group) Co., Ltd.'s wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its product "Polyvinyl Alcohol Embolization Microspheres" [1] Group 2 - The product "Polyvinyl Alcohol Embolization Microspheres" is a new medical device aimed at enhancing treatment options in the healthcare sector [1]

Core Viewpoint - The company, Xinmai Medical (688016.SH), has received a medical device registration certificate from the National Medical Products Administration for its polyethylene glycol embolization microspheres, marking a significant advancement in interventional oncology treatment options [1] Group 1: Product Development - The polyethylene glycol embolization microspheres, named FinderSphere®/Night Pearl™, are the company's first embolization product developed for interventional oncology [1] - This product aims to provide more precise and efficient treatment options for Transarterial Chemoembolization (TACE) procedures, benefiting a larger number of cancer patients in China [1] Group 2: Existing and Pipeline Products - In addition to the new product, the company has already launched the Tipspear®/Piercing Arrow™ transjugular intrahepatic portosystemic shunt (TIPS) kit in China [1] - The company is also developing several other products in the interventional oncology field, including the innovative medical device HepaFlow®/Bridge to the Sky™ TIPS covered stent system, as well as hemostatic occlusion systems and microcatheters [1] Group 3: Future Commitment - The company is committed to the innovative research and application promotion of high-end medical devices in aortic, peripheral vascular, and interventional oncology fields, aiming to benefit more patients both domestically and internationally [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tuomai Medical, has received a medical device registration certificate from the National Medical Products Administration for a polyethylene glycol embolization microsphere, marking a significant advancement in the company's interventional oncology product line [1] Group 1 - The registration certificate number is Guo Xie Zhu Ren 20263130187, valid from January 28, 2026, to January 27, 2031 [1] - The product is classified as a Class III medical device, intended for embolization treatment of hypervascular malignant tumors in solid organs [1] - This product represents the company's first embolization product in the field of tumor interventional therapy, potentially offering improved treatment options [1] Group 2 - The product must obtain a production license before it can be sold, and the sales situation remains uncertain, making it difficult to predict its impact on revenue [1]